Amgen Faces Potential $7.1 Billion IRS Fine; Are Other Drugmakers at Risk?

By PacConAdmin | April 28, 2022

Amgen disclosed this week that the Internal Revenue Service (IRS) is seeking $7.1 billion in back taxes and fines relating to how the drugmaker split profits between its U.S. and Puerto Rican manufacturing hubs.
Source: Drug Industry Daily

Posted in Drug Industry Daily